Monday, January 14, 2019
HCA Healthcare initiated at Stephens
HCA Healthcare initiated with an Overweight at Stephens. Stephens analyst Scott Fidel initiated coverage of 11 Managed Care and Healthcare Facilities stocks, telling investors that overall he is constructive on managed care and selective on hospitals. He started HCA Healthcare with an Overweight rating and $143 price target, noting that its fundamental performance accelerated across all key metrics in 2018 and the company has already signaled that EBITDA growth trends could again exceed its long-term targets in 2019.
https://thefly.com/landingPageNews.php?id=2848051
Galmed price target lowered to $28 from $36 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce lowered his price target for Galmed Pharmaceuticals to $28 after shifting the U.S. launch of Aramchol out to 2022 from 2021 previously. However, with a pivotal path forward for Aramchol, which the analyst notes has been granted Fast Track designation by the FDA for the treatment of nonalcoholic steatohepatitis, he affirms a Buy rating on Galmed shares.
https://thefly.com/landingPageNews.php?id=2848053
Molina Healthcare initiated at Stephens
Molina Healthcare initiated with an Equal Weight at Stephens. Stephens analyst Scott Fidel initiated coverage of 11 Managed Care and Healthcare Facilities stocks, telling investors that overall he is constructive on managed care and selective on hospitals. He started Molina Healthcare with an Equal Weight rating and $144 price target, stating that while he sees a number of revenue and margin improvement opportunities, the 3.2% net margin Molina is expected to achieve in 2018 has historically been a difficult level of profitability to sustain for MCOs in highly-subsidized government-sponsored business lines.
https://thefly.com/landingPageNews.php?id=2848061
WellCare initiated at Stephens
WellCare initiated with an Overweight at Stephens. Stephens analyst Scott Fidel initiated coverage of 11 Managed Care and Healthcare Facilities stocks, telling investors that overall he is constructive on managed care and selective on hospitals. He started WellCare with an Overweight rating and $276 price target. He sees the key growth event for Medicaid in 2019 being the $6.4B North Carolina RFP contract awards in February and lists WellCare as among the companies that could win contracts.
https://thefly.com/landingPageNews.php?id=2848089
Endo CCH asset remain underappreciated, says Canaccord
Canaccord analyst Dewey Steadman met with Endo management and came away with the belief the Street continues to undervalue the CCH asset. He believes CCH, along with strong core business performance and relatively manageable cash outflows, make for a compelling story with the shares attractively priced. Steadman reiterated his Buy rating and $20 price target on Endo shares.
https://thefly.com/landingPageNews.php?id=2848101
Evolent Health weakness a buying opportunity, says Canaccord
Canccord analyst Richard Close said the recent weakness in Evolent Health is a buying opportunity as the long-term outlook remains favorable. The analyst cited positive commentary by regulators on the need to transition from fee-for-service reimbursement to value-based care payment models. He also noted management commentary at the JP Morgan conference last week on headwinds the company will be encountering in 2019 and he lowered his estimates accordingly. Close reiterated his Buy rating and lowered his price target to $25 from $28 on Evolent Health shares.
https://thefly.com/landingPageNews.php?id=2848103
Subscribe to:
Posts (Atom)